Why COVID-19 lungs fail: tiny blood vessel damage may be key

NCT ID NCT05074758

Completed Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study investigates why COVID-19 causes severe lung injury (ARDS) by looking at tiny blood vessels in the lungs. Researchers will compare 39 patients with COVID-19 ARDS to those with ARDS from other causes. They measure 'alveolar dead space' — lung areas that get air but not blood flow — and check blood for signs of vessel damage and clotting problems. The goal is to understand if COVID-19 uniquely harms lung blood vessels, which could guide future treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors better predict outcomes and tailor treatments for COVID-19 patients with severe lung injury.
What could go wrong: This is a small observational study, not a treatment trial. It may not identify clear differences or lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS, HUMAN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARDS, HUMAN COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME

Contacts and locations

Show contact details

Locations

Hôpital européen Georges Pompidou

Paris, Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.